Cargando…

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelnabi, Rana, Foo, Caroline S., Jochmans, Dirk, Vangeel, Laura, De Jonghe, Steven, Augustijns, Patrick, Mols, Raf, Weynand, Birgit, Wattanakul, Thanaporn, Hoglund, Richard M., Tarning, Joel, Mowbray, Charles E., Sjö, Peter, Escudié, Fanny, Scandale, Ivan, Chatelain, Eric, Neyts, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847371/ https://www.ncbi.nlm.nih.gov/pubmed/35169114 http://dx.doi.org/10.1038/s41467-022-28354-0

Ejemplares similares

Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model
por: Foo, Caroline S., et al.
Publicado: (2022)

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
por: Assmus, Frauke, et al.
Publicado: (2022)

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect
por: Foo, Caroline S., et al.
Publicado: (2022)

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment
por: Abdelnabi, Rana, et al.
Publicado: (2023)

Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
por: Shekhar, Chandra, et al.
Publicado: (2022)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
por: Driouich, Jean-Sélim, et al.
Publicado: (2022)

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
por: Heskin, Joseph, et al.
Publicado: (2022)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M(pro)
por: Ngo, Son Tung, et al.
Publicado: (2022)

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
por: Hau, Raymond K., et al.
Publicado: (2022)

Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M(pro) inhibitor in animal models
por: Catlin, N.R., et al.
Publicado: (2022)

Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
por: Wattanakul, Thanaporn, et al.
Publicado: (2021)

Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332
por: Pavan, Matteo, et al.
Publicado: (2021)

Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
por: Wouters, Elise, et al.
Publicado: (2023)

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
por: Ahmad, Bilal, et al.
Publicado: (2021)

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
por: Vandyck, Koen, et al.
Publicado: (2021)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
por: Vangeel, Laura, et al.
Publicado: (2022)

Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies
por: Braeckmans, Marlies, et al.
Publicado: (2022)

EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
por: Majda, T, et al.
Publicado: (2022)

Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis
por: Panjasawatwong, Navarat, et al.
Publicado: (2020)

Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase
por: Kasprzyk, Renata, et al.
Publicado: (2021)

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers
por: Chotsiri, Palang, et al.
Publicado: (2017)

Chloroquine, an Anti-Malaria Drug as Effective Prevention for Hantavirus Infections
por: Vergote, Valentijn, et al.
Publicado: (2021)

Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery
por: Chiu, Winston, et al.
Publicado: (2023)

Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues
por: Persoons, Leentje, et al.
Publicado: (2021)

Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells
por: Vanhoutte, Roeland, et al.
Publicado: (2023)

Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT
por: Alvarado, Ysaias José, et al.
Publicado: (2022)

A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
por: Do, Thuc Nguyen Dan, et al.
Publicado: (2021)

Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats
por: López-Yerena, Anallely, et al.
Publicado: (2020)

Correction: López-Yerena, A., et al. “Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats” Pharmaceutics 2020, 12, 134
por: López-Yerena, Anallely, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8s91r08p23ukdc630u01s7tfo8